In a retrospective case series (n=19) of treatment‑resistant depression patients treated with psilocybin (20–35 mg) in routine clinical practice, depressive symptoms decreased significantly with large effect sizes on MADRS and BDI, though response and remission rates were lower than in controlled trials and no additive benefit of multiple doses was found.
- Published
- Journal
- The Lancet Regional Health – Europe
- Authors
- Jungwirth, J., Westenhöfer, S., Aicher, H., Provaznikova, B., Kronenberg, G., Seifritz, E., Prinz, S., Olbrich, S.